Sapporo National Hospital

Recent papers from Sapporo National Hospital

1. Cancer of Unknown Primary in Transition: From Empirical Chemotherapy to Immunotherapy and Molecularly Guided TreatmentAsia-Pacific Journal of Clinical Oncology · 2026
2. Initial dose of fruquintinib and clinical outcomes in patients with refractory metastatic colorectal cancer: a multicenter real-world studyBMC Cancer · 2026
3. Long-Term Survival Outcomes of Modified-FOLFOXIRI Plus Cetuximab Versus Bevacizumab in RAS / BRAF Wild-Type Metastatic Colorectal Cancer: Final Analysis of the DEEPER TrialJournal of Clinical Oncology · 2026
4. Cardiac Ankyrin Repeat Protein Gene (ANKRD1) Mutations in Hypertrophic CardiomyopathyJournal of the American College of Cardiology · 2009
5. DVH parameters and gastrointestinal/genitourinary toxicities in moderate hypofractionated salvage radiotherapy after radical prostatectomyJournal of Radiation Research · 2026
6. Impact of Thyroid Transcription Factor‐1 Expression on Outcomes of Platinum‐Based Chemoimmunotherapy in Advanced or Recurrent Non‐Squamous Non‐Small Cell Lung CancerThoracic Cancer · 2026
7. Author Correction: SEZ6-targeting antibody−drug conjugate ABBV-706 in advanced small cell lung cancer and solid tumors: a phase 1 trialNature Medicine · 2026
8. Quality of life with palbociclib plus tamoxifen in hormone receptor-positive, HER2-negative advanced breast cancer: results from PATHWAY, an Asian international, double-blind, randomized phase 3 trialBreast Cancer · 2026
9. Afatinib Versus Osimertinib for Non‐Small Cell Lung Cancer With Uncommon EGFR Mutations: Real‐World OutcomesCancer Science · 2026
10. Paclitaxel plus bevacizumab with or without atezolizumab for hormone receptor-positive/HER2-negative advanced breast cancer: JCOG1919E (AMBITION) phase III trial.Journal of Clinical Oncology · 2026
11. AI-driven TILs spatial analysis to identify high-density hot spots as a superior prognostic marker in triple-negative breast cancer.Journal of Clinical Oncology · 2026
12. A randomized phase III trial of dexamethasone mouthwash to prevent chemotherapy-induced oral mucositis in patients with breast cancer.Journal of Clinical Oncology · 2026
13. ABBV-706 as monotherapy and in combination with budigalimab in patients with relapsed/refractory (R/R) small cell lung cancer (SCLC).Journal of Clinical Oncology · 2026
14. Final results of a randomized phase II trial of second-line treatment for advanced soft tissue sarcoma comparing trabectedin, eribulin, and pazopanib: 2ND-STEP study, JCOG1802.Journal of Clinical Oncology · 2026
15. Prior response to anti-VEGF agents predicts the efficacy of trifluridine/tipiracil plus bevacizumab in patients with metastatic colorectal cancer.2026
16. Objective response rate predicts survival in recurrent or metastatic head and neck squamous cell carcinoma treated with immune checkpoint blockade but not with targeted therapy: A retrospective multicenter studyCancer · 2026
17. Haemodynamic early outcomes of sinus plication for bicuspid aortic valve repairInterdisciplinary CardioVascular and Thoracic Surgery · 2026
18. Association of immune-related adverse events with survival in patients receiving immune checkpoint inhibitor plus chemotherapy for lung cancerScientific Reports · 2026
19. Sacituzumab govitecan in Japanese participants with HR+/HER2− metastatic breast cancer: primary results from the phase II ASCENT-J02 studyJapanese Journal of Clinical Oncology · 2026
20. Proton-pump inhibitors and palbociclib or abemaciclib in endocrine-sensitive breast cancer treatmentSHILAP Revista de lepidopterología · 2026